Commercialisation of biotechnology: Do dedicated public policies matter?

Science and Public Policy

Volumn 31, Issue 5, 2004, Pages 371-383

  Enzing, Christien ^a   van der Giessen, Annelieke ^a   Kern, Sander ^a  

^a TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; COMMERCIALIZATION; INDUSTRIAL PERFORMANCE; TECHNOLOGY POLICY;

EASTERN HEMISPHERE; EURASIA; EUROPE; WORLD;

EID: 7044274587     PISSN: 03023427     EISSN: None     Source Type: Journal    
DOI: 10.3152/147154304781779868     Document Type: Article

References (15)

1. Allansdottir, A, A Bonaccorsi, A Gambardella, M Mariani, L Orsenigo, F Pammolli and M Riccaboni (2002), "Innovation and competitiveness in the European biotechnology", Enterprise Papers no 7, report commissioned by the European Commission, DG Enterprise, as background paper for the Competitiveness Report 2001.
2. Colombo, Massimo G, and Marco Delmastro (2002), "How effective are technology incubators? Evidence from Italy", Research Policy, 31(7), September, pages 1103-1122.
3. Enzing et al (1999), Inventory of Public Biotech R&D Programmes in Europe - Volume I: Analytical Report (Office for Official Publications of the European Communities, Luxembourg).
4. Ernst and Young (2001), Integration: Ernst and Young's Eighth Annual European Life Sciences Report 2001 (Ernst and Young International, London.
5. European Commission (2002), Life Sciences and Biotechnology, a strategy for Europe, Communication from the Commission to the Council, the European Parliament, The Economic and Social Committee and the Committee of the Regions, COM(2002)27 final, Brussels, Belgium, 23 January.
6. European Commission (2003), 2002 European Innovation Scoreboard Technical Paper 7 Biotechnology Innovation Scoreboard (DG Enterprise, Brussels) available at , last accessed 31 August 2004.
7. EVCA, European Private Equity and Venture Capital Association (2002), Yearbook 2002 - Annual Survey 2001 (ECVA, Brussels).
8. George, Gerard, Shaker A Zahra and D Robley Wood Jr (2002), "The effects of business-university alliances on innovative output and financial performance: a study of publicly traded biotechnology companies", Journal of Business Venturing, 17(6), October, pages 577-609.
9. Kern, S, and CM Enzing (2003), "The interplay between national, sectoral and technological determinants in innovation systems in Europe: the case of biotechnology", paper presented at the international conference Innovation in Europe: institutions, values and dynamics, Roskilde, Denmark, May.
10. McKelvey, M D (1996), Evolutionary Innovations. The Business of Biotechnology (Oxford University Press, Oxford).
11. McKelvey, M D, H Alm and M Riccaboni (2003), "Does co-location matter for formal knowledge collaboration in the Swedish biotechnology-pharmaceutical sector?", Research Policy, 32(3 , March, pages 483-501.
12. Ndonzuau, Frédéric Nlemvo, Fabrice Pirnay and Bernard Surlemont (2002), "A stage model of academic spin-off creation" , Technovation 22(5), May, pages 281-289.
13. Reiss, T, J Calvert, I Dominguez Lacasa, C Enzing, A van der Giessen, S Hinze, S Kern, V Mangematin, L Nesta, P Patel and J Senker (2003), Efficiency of Innovation Policies in High Technology Sectors in Europe (EPOHITE), EUR 20904 (Final report), EUR 29022 (national case studies) (Office for Official Publications of the European Communities, Luxembourg, catalogue no KI-NA-20-904-EN-C).
14. Senker, J, P van Zwanenberg, Y Caloghirou, S Zambarloukos, F Kolisis, C Enzing, S Kern, V Mangematin, R Martinsen, E Muñoz, V Diaz, J Espinosa, S O'Hara, K Burke, T Reiss and S Wörner (2001), European Biotechnology Innovation Systems (Final Report) (SPRU, Brighton, UK).
15. Storey, D J, and B S Tether (1998), "Public policy measures to support new technology-based firms in the European Union", Research Policy 26(9), April, pages 1037-1057.